WALTHAM, Mass., January 9, 2023 – Conjugate Group, a Flexible Drug Development service provider to the biopharma industry, has named Andrew J. Young CEO of the company.

As a response to the company’s robust growth in 2022 and plans to continue expansion into 2023 and beyond, the Founding Partners felt it was critical to formalize the Company’s leadership and accountability structure.

“Andrew has been instrumental in building Company operations, and in day-to-day leadership of the organization,” said Sean Malkus, Co-Founder and Managing Partner. “Formalizing his role as CEO is a natural extension of the work he has already been doing, and will allow the organization to operate efficiently as it grows.”

Andrew Young has over 20 years of experience in life science services. Prior to co-founding The Conjugate Group, Andrew co-founded and led BioBridges prior to its acquisition. He brings valuable leadership experience in both consulting/contract services and the Life Sciences industry to Conjugate Group. His leadership will be key to the company’s continued growth.

Sean Malkus and Jesse Nandhavan, the other Founding Partners of The Conjugate Group, will remain Managing Partners of the firm, and together with Andrew will provide strategic direction and leadership to the organization.

About The Conjugate Group

Founded in 2017, Conjugate Group provides Flexible Drug Development services to clients in the biopharmaceutical industry, with a focus on the clinical development lifecycle. A leader in Consulting and Contract Services, we offer individual resources, full-function outsourcing, and milestone-focused tactical teams to help our clients operate effectively and efficiently.  We have helped numerous companies move products into and through the Clinic, from initial IND through registration and commercial launch.